Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting

Stock Information for Cross Timbers Royalty Trust

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cross Timbers Royalty Trust

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin Announces Reverse Stock Split
Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.